Genetics & DNA
4 articles with genetic insights and evidence-tiered analysis.
CYP3A4 Slow Metabolizer Guide: What Peptide Users Must Know
If you carry the CYP3A4*22 variant, standard drug doses can build to 150-170% of intended levels. Here is what that means for your peptide stack.
Semaglutide Non-Responders: The Gene Behind the Gap
A 27,885-person study found the gene that predicts who loses weight fast on semaglutide and who barely moves. Your DNA already has the answer.
What Your 23andMe Data Can Actually Tell You About Peptides
Your 23andMe raw file is a survey of 650,000 known variants. Here is which peptide-response SNPs it reliably genotypes, what gaps exist across chip versions, and why the data is more useful than most realize.
Semaglutide and Your Genetics: Why Ozempic Works Differently for Everyone
10-17% of semaglutide users are non-responders. New genetic research — including a 27,885-person GWAS from 23andMe — reveals why. Your GLP1R, TCF7L2, and ARRB1 variants determine whether you'll lose 15% of your body weight or barely notice a difference.